For hidradenitis suppurativa, bimekizumab has shown promising results.

Published Date: 05 Apr 2023

According to research presented at the American Academy of Dermatology's annual meeting in March, bimekizumab shows promise in phase 3 trials for people with moderate-to-severe hidradenitis suppurativa (HS).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot